CliffBio
small molecule

METHSUXIMIDE

METHSUXIMIDE

Loss of exclusivity—loss of exclusivity
CompanyNovitium Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameMETHSUXIMIDE
Active ingredientMETHSUXIMIDE
Strength300MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2023
Marketing statusRX

More from Novitium Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.